Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.86 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22458251 | 1.00 | TYMP (0.86) | TYMPADORA1SLC29A1PRKAG1PRKAA1 | |
| SCHEMBL29649690 | 1.00 | TYMP (0.86) | TYMPADORA1SLC29A1PRKAG1PRKAA1 | |
| SCHEMBL29649671 | 1.00 | TYMP (0.86) | TYMPADORA1SLC29A1PRKAG1PRKAA1 | |
| SCHEMBL5270000 | 0.93 | TYMP (1.00) | TYMPADORA1SLC29A1 | |
| SCHEMBL22458597 | 0.93 | TYMP (1.00) | TYMPADORA1SLC29A1 | |
| SCHEMBL1796310 | 0.93 | TYMP (1.00) | TYMPADORA1SLC29A1 | |
| SCHEMBL21878051 | 0.93 | TYMP (0.74) | TYMPADORA1SLC29A1 | |
| SCHEMBL29792948 | 0.93 | TYMP (0.74) | TYMPADORA1SLC29A1 | |
| SCHEMBL29792945 | 0.93 | TYMP (0.74) | TYMPADORA1SLC29A1 | |
| SCHEMBL20579728 | 0.91 | TYMP (0.72) | TYMPADORA1SLC29A1PRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939988-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NOVEL AZOLOPYRIMIDINE HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2022-01-19 | — | — | EP | disclosed |